Tumor endothelial cell targeted cyclic RGD-modified heparin derivative

Inhibition of angiogenesis and tumor growth

Kyeongsoon Park, Yoo Shin Kim, Gee Young Lee, Rang Woon Park, In-San Kim, Sang Yoon Kim, Youngro Byun

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose. We prepared tumor endothelium targeted cRGD-modified heparin derivative (cRGD-HL) by coupling heparin-lithocholic acid (HL) with cRGDyK, and evaluated inhibition effects of cRGD-HL on angiogenesis and tumor growth. Methods. To evaluate antiangiogenic activity of cRGD-HL, we performed tests on endothelial cell adhesion and migration to vitronectin, tube formation, binding affinity to purified αvβ3 integrin, and in vivo Matrigel plug assay. The antitumor activity of cRGD-HL was also evaluated by monitoring tumor growth and microvessel formation in squamous cell carcinoma (SCC7) tumor. Results. The cRGD-HL significantly inhibited adhesion and migration of endothelial cells to vitronectin, and tubular structures of endothelial cells. Compared to cRGDyK and HL, cRGD-HL has high binding affinity to purified αvβ3 integrin. The enhanced antiangiogenic effect of cRGD-HL was confirmed in Matrigel assay by showing the significant inhibition of bFGF-driven angiogenesis and blood vessel formation. It was thought that potent antiangiogenic effect of cRGD-HL was probably due to the interference of αvβ3-mediated interaction, resulting in the enhanced antitumoral activity against SCC7 tumor. Conclusion. These results demonstrated that cRGD-modified heparin derivative enhanced anti-angiotherapeutic effects against solid tumor, and therefore, it could be applied to treat various cancers and angiogenic diseases as a potent angiogenesis inhibitor.

Original languageEnglish
Pages (from-to)2786-2798
Number of pages13
JournalPharmaceutical research
Volume25
Issue number12
DOIs
Publication statusPublished - 2008 Dec 1
Externally publishedYes

Fingerprint

Lithocholic Acid
Endothelial cells
Heparin
Tumors
Endothelial Cells
Derivatives
Growth
Neoplasms
Vitronectin
Integrins
cyclic arginine-glycine-aspartic acid peptide
Assays
Angiogenesis Inhibitors
Cell adhesion
Blood vessels
Microvessels
Cell Adhesion
Endothelium
Cell Movement
Blood Vessels

Keywords

  • Angiogenesis
  • Heparin derivative
  • Lithocholic acid
  • RGD
  • SCC7

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Tumor endothelial cell targeted cyclic RGD-modified heparin derivative : Inhibition of angiogenesis and tumor growth. / Park, Kyeongsoon; Kim, Yoo Shin; Lee, Gee Young; Park, Rang Woon; Kim, In-San; Kim, Sang Yoon; Byun, Youngro.

In: Pharmaceutical research, Vol. 25, No. 12, 01.12.2008, p. 2786-2798.

Research output: Contribution to journalArticle

Park, Kyeongsoon ; Kim, Yoo Shin ; Lee, Gee Young ; Park, Rang Woon ; Kim, In-San ; Kim, Sang Yoon ; Byun, Youngro. / Tumor endothelial cell targeted cyclic RGD-modified heparin derivative : Inhibition of angiogenesis and tumor growth. In: Pharmaceutical research. 2008 ; Vol. 25, No. 12. pp. 2786-2798.
@article{71cc7cfedc28474b95ff7853a57a6bec,
title = "Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: Inhibition of angiogenesis and tumor growth",
abstract = "Purpose. We prepared tumor endothelium targeted cRGD-modified heparin derivative (cRGD-HL) by coupling heparin-lithocholic acid (HL) with cRGDyK, and evaluated inhibition effects of cRGD-HL on angiogenesis and tumor growth. Methods. To evaluate antiangiogenic activity of cRGD-HL, we performed tests on endothelial cell adhesion and migration to vitronectin, tube formation, binding affinity to purified αvβ3 integrin, and in vivo Matrigel plug assay. The antitumor activity of cRGD-HL was also evaluated by monitoring tumor growth and microvessel formation in squamous cell carcinoma (SCC7) tumor. Results. The cRGD-HL significantly inhibited adhesion and migration of endothelial cells to vitronectin, and tubular structures of endothelial cells. Compared to cRGDyK and HL, cRGD-HL has high binding affinity to purified αvβ3 integrin. The enhanced antiangiogenic effect of cRGD-HL was confirmed in Matrigel assay by showing the significant inhibition of bFGF-driven angiogenesis and blood vessel formation. It was thought that potent antiangiogenic effect of cRGD-HL was probably due to the interference of αvβ3-mediated interaction, resulting in the enhanced antitumoral activity against SCC7 tumor. Conclusion. These results demonstrated that cRGD-modified heparin derivative enhanced anti-angiotherapeutic effects against solid tumor, and therefore, it could be applied to treat various cancers and angiogenic diseases as a potent angiogenesis inhibitor.",
keywords = "Angiogenesis, Heparin derivative, Lithocholic acid, RGD, SCC7",
author = "Kyeongsoon Park and Kim, {Yoo Shin} and Lee, {Gee Young} and Park, {Rang Woon} and In-San Kim and Kim, {Sang Yoon} and Youngro Byun",
year = "2008",
month = "12",
day = "1",
doi = "10.1007/s11095-008-9643-y",
language = "English",
volume = "25",
pages = "2786--2798",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Tumor endothelial cell targeted cyclic RGD-modified heparin derivative

T2 - Inhibition of angiogenesis and tumor growth

AU - Park, Kyeongsoon

AU - Kim, Yoo Shin

AU - Lee, Gee Young

AU - Park, Rang Woon

AU - Kim, In-San

AU - Kim, Sang Yoon

AU - Byun, Youngro

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Purpose. We prepared tumor endothelium targeted cRGD-modified heparin derivative (cRGD-HL) by coupling heparin-lithocholic acid (HL) with cRGDyK, and evaluated inhibition effects of cRGD-HL on angiogenesis and tumor growth. Methods. To evaluate antiangiogenic activity of cRGD-HL, we performed tests on endothelial cell adhesion and migration to vitronectin, tube formation, binding affinity to purified αvβ3 integrin, and in vivo Matrigel plug assay. The antitumor activity of cRGD-HL was also evaluated by monitoring tumor growth and microvessel formation in squamous cell carcinoma (SCC7) tumor. Results. The cRGD-HL significantly inhibited adhesion and migration of endothelial cells to vitronectin, and tubular structures of endothelial cells. Compared to cRGDyK and HL, cRGD-HL has high binding affinity to purified αvβ3 integrin. The enhanced antiangiogenic effect of cRGD-HL was confirmed in Matrigel assay by showing the significant inhibition of bFGF-driven angiogenesis and blood vessel formation. It was thought that potent antiangiogenic effect of cRGD-HL was probably due to the interference of αvβ3-mediated interaction, resulting in the enhanced antitumoral activity against SCC7 tumor. Conclusion. These results demonstrated that cRGD-modified heparin derivative enhanced anti-angiotherapeutic effects against solid tumor, and therefore, it could be applied to treat various cancers and angiogenic diseases as a potent angiogenesis inhibitor.

AB - Purpose. We prepared tumor endothelium targeted cRGD-modified heparin derivative (cRGD-HL) by coupling heparin-lithocholic acid (HL) with cRGDyK, and evaluated inhibition effects of cRGD-HL on angiogenesis and tumor growth. Methods. To evaluate antiangiogenic activity of cRGD-HL, we performed tests on endothelial cell adhesion and migration to vitronectin, tube formation, binding affinity to purified αvβ3 integrin, and in vivo Matrigel plug assay. The antitumor activity of cRGD-HL was also evaluated by monitoring tumor growth and microvessel formation in squamous cell carcinoma (SCC7) tumor. Results. The cRGD-HL significantly inhibited adhesion and migration of endothelial cells to vitronectin, and tubular structures of endothelial cells. Compared to cRGDyK and HL, cRGD-HL has high binding affinity to purified αvβ3 integrin. The enhanced antiangiogenic effect of cRGD-HL was confirmed in Matrigel assay by showing the significant inhibition of bFGF-driven angiogenesis and blood vessel formation. It was thought that potent antiangiogenic effect of cRGD-HL was probably due to the interference of αvβ3-mediated interaction, resulting in the enhanced antitumoral activity against SCC7 tumor. Conclusion. These results demonstrated that cRGD-modified heparin derivative enhanced anti-angiotherapeutic effects against solid tumor, and therefore, it could be applied to treat various cancers and angiogenic diseases as a potent angiogenesis inhibitor.

KW - Angiogenesis

KW - Heparin derivative

KW - Lithocholic acid

KW - RGD

KW - SCC7

UR - http://www.scopus.com/inward/record.url?scp=57149126267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149126267&partnerID=8YFLogxK

U2 - 10.1007/s11095-008-9643-y

DO - 10.1007/s11095-008-9643-y

M3 - Article

VL - 25

SP - 2786

EP - 2798

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 12

ER -